Navigation Links
Urologists Outraged over Government Panel's Recommendation to Stop Life-Saving Prostate Cancer Testing
Date:5/21/2012

TALLAHASSEE, Fla., May 21, 2012 /PRNewswire/ -- The Large Urology Group Practice Association (LUGPA), representing more than 1,800 urologists, today discredited recommendations by the U.S. Preventive Services Task Force (USPSTF) to stop prostate cancer testing.

USPSTF's final recommendation, released today, instructs physicians to discourage asymptomatic men from having the PSA test. This comes despite overwhelming opposition from urologists, prostate cancer patients, and patient advocacy groups, all who have confirmed the importance of these life-saving measures.

"We are appalled at the USPSTF's recommendation that healthy men should no longer receive prostate-specific antigen (PSA) blood tests as part of routine cancer screening," said Dr. Deepak A. Kapoor, President of LUGPA and Chairman and CEO of Integrated Medical Professionals, PLLC. Kapoor added, "Failing to detect cancer early will create a public health catastrophe in 5-10 years."

The largest study on screening, the European Randomized Study for the Screening of Prostate Cancer (ERSPC) published its updated findings in the March issue of the New England Journal of Medicine. This demonstrated a 21 percent survival advantage to PSA screening for all patients, and furthermore, for those with the longest follow-up (over 10 years) this increased to 38 percent.  This is consistent with experience in the United States, where death rates from prostate cancer have declined by nearly 40 percent over the last two decades, although the incidence of the disease has been relatively stable.

Dr. Kapoor states, "USPSTF clearly 'cherry-picked' data to support what can only be viewed as a pre-conceived bias against screening.  The task force did not include any physician who treats prostate cancer, and ignored credible studies and epidemiological data demonstrating a significant survival advantage to early detection…we
'/>"/>

SOURCE Large Urology Group Practice Association
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Urologists Debunk Misleading, Grossly Inaccurate Prostate Cancer Biopsy Study
2. JoVE partners with US government to publish cutting-edge defense research
3. Potassium Iodide Sales Surge on Heels of Large Government Order
4. BioPower Systems Awarded $5 Million from Victorian Government
5. McGladrey Manufacturing and Distribution MonitorĀ® Shows Business Accelerating Despite Concerns About Government Gridlock
6. GeoVax Awarded $3.6 Million Grant by U.S. Government for its HIV/AIDS Vaccine Program
7. Healthcare Distribution Management Association Names Patrick Kelly New Senior Vice President, Government Affairs
8. University of Utah and Navigen Pharmaceuticals Announce a New Government Contract to Advance Slit2N for the Treatment of Hemorrhagic Fever and Anthrax Exposure
9. The Israeli Governments Ministry of Health Invites Medisafe 1 Technologies to Demonstrate its Unique Syringe Locking Device Technology
10. Transgenomic Awarded $1,070,453 From U.S. Government Under the Patient Protection and Affordable Care Act
11. U.S. Government Grants Awarded for Further Development of Adult Stem Cell Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... Leading ... clinical study of its canine osteoarthritis stem cell product, currently under development for ... KS) and will be marketed in the US by Aratana. This product, termed ...
(Date:7/30/2015)... over 60,000 customers across the globe, ISN improves the efficiency and effectiveness of contractor ... 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... 2015  Discovery Laboratories, Inc. (Nasdaq: DSCO ... second $1.0M tranche under a previously awarded Phase ... at up to $3.0 million to support continued ... a potential medical countermeasure to mitigate acute and ... an initial $1.0 million under this grant in ...
(Date:7/29/2015)... , July 30, 2015 ... reports results for the second quarter of 2015. ... group,s results and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics ... Q2 results - Performance drivers ...
Breaking Biology Technology:VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3
... Rapid Production, Increased Bioavailability, MOUNTAIN VIEW, Calif., ... are either incurable or difficult to treat allures ... prized, due to their,therapeutic potential, stem cell therapies ... Stem cell research progresses at a fast pace; ...
... Inc. (Nasdaq: CEPH ) and Eurand NV ... Paragraph IV Certification Notice Letter on October 20, ... to the U.S.,Food and Drug Administration (FDA) by ... a generic version of the 15 mg and,30 ...
... 71% of Evaluable Patients in the Trial,s First Stage ... Achieved Objective Tumor Responses- ... Second Stage-, TUSTIN, Calif., Oct. 21 Peregrine,Pharmaceuticals, Inc. (Nasdaq: ... cancer and serious viral,infections, today announced that updated preliminary data from ...
Cached Biology Technology:Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 2Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 2Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 3Cephalon and Eurand Announce Notification of Generic Filing for Cyclobenzaprine Hydrochloride Extended-Release Capsules 4Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports Progress in Its Phase II Trial of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer 4
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/7/2015)... MOUNTAIN VIEW, Calif. , July 7, 2015 ... mobile biometrics market, Frost & Sullivan recognizes Credence ... & Sullivan Entrepreneurial Company of the Year ... product suite to aid in its mission of ... and under-recognized populations globally. As Credence ID was ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting ... the addition of two new team members. ... David Raviv will act as head of strategic ... to providing the most secure solutions for the enterprise market. ... 7 Technologies, a provider of security and management products, which ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... 2005 discovery of an enzyme that is a natural ... Diego (UCSD) School of Medicine have now identified two ... for therapies to treat diabetes, heart and neurological disease. ... professor of pharmacology, and colleagues are published in the ...
... years, orthopedic surgeon Dennis Crawford, M.D., Ph.D., of Oregon ... tissue for transplant to treat some of his patients ... this unfortunate and ironic," explained Crawford, assistant professor of ... and a specialist in sports medicine. "Oregonians, it turns ...
... cancer care was $2.3 billion in the first year after diagnosis, ... the Journal of the National Cancer Institute . The time ... cancer care varied widely, they write. , Several studies have ... attempted to include a patient's time associated with cancer care, such ...
Cached Biology News:UCSD researchers discover variants of natural tumor suppressor 2OHSU surgeon implants donated tissue allografts 2Study calculates patient time costs associated with cancer care 2Study calculates patient time costs associated with cancer care 3
... Mouse monoclonal [PRMT5-21] to PRMT5 Arginine ... which has only recently been linked to ... PRMT enzymes have been identified in mammalian ... have essential regulatory functions by methylation of ...
... complete kit contains enough separation ... a total of 5 x ... includes the StemSep red magnet ... and buffers for the specific ...
... Exiqons LNA technology enables sensitive, fast and ... intact chromosomes. Short hybridisation time ... cells and chromosome spreads Multiplex capability ... probes Probes available with ...
... dehydrogenase catalyzes a reversible reaction between ... with NAD as a coenzyme. GPDH ... progenitor cells into adipocytes and, thus, ... been used as an index for ...
Biology Products: